NASDAQ:PODD Insulet - PODD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. $286.20 +0.70 (+0.25%) (As of 01/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$283.00▼$289.9950-Day Range$279.72▼$313.0052-Week Range$181.00▼$320.00Volume370,195 shsAverage Volume349,475 shsMarket Capitalization$19.88 billionP/E Ratio1,192.50Dividend YieldN/APrice Target$309.23 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Insulet MarketRank™ ForecastAnalyst RatingModerate Buy2.64 Rating ScoreUpside/Downside9.0% Upside$312.08 Price TargetShort InterestBearish3.15% of Shares Sold ShortDividend StrengthN/ASustainability-1.20Upright™ Environmental ScoreNews Sentiment0.57Based on 8 Articles This WeekInsider TradingSelling Shares$8.51 M Sold Last QuarterProj. Earnings Growth17.24%From $0.87 to $1.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector561st out of 1,055 stocksSurgical & Medical Instruments Industry58th out of 106 stocks 2.3 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Buy. The company's average rating score is 2.62, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $312.08, Insulet has a forecasted upside of 9.0% from its current price of $286.20.Amount of Analyst CoverageInsulet has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.15% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Insulet has recently increased by 2.34%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Insulet is -1.20. Previous Next 2.5 News and Social Media Coverage News SentimentInsulet has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Insulet this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.MarketBeat Follows4 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,507,309.00 in company stock.Percentage Held by InsidersOnly 0.90% of the stock of Insulet is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 17.24% in the coming year, from $0.87 to $1.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 1,192.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 138.74.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 1,192.50, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 156.64.Price to Book Value per Share RatioInsulet has a P/B Ratio of 35.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Insulet (NASDAQ:PODD) StockInsulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.Read More Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address PODD Stock News HeadlinesJanuary 18, 2023 | marketbeat.comInsulet Has Potential To Gain More Than Analysts Are ForecastingEven as it pulled back with the broader market Tuesday, insulin pump maker Insulet found support along its 50-day line and remained in possible buy range.January 27, 2023 | americanbankingnews.comInsulet (NASDAQ:PODD) Coverage Initiated by Analysts at Wolfe ResearchJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 25, 2023 | finance.yahoo.comInsulet (PODD) Dips More Than Broader Markets: What You Should KnowJanuary 22, 2023 | americanbankingnews.comInsulet Co. (NASDAQ:PODD) Receives $309.23 Consensus PT from AnalystsJanuary 17, 2023 | finance.yahoo.comDow Jones Futures Drop Ahead Of Manufacturing Data; Goldman Sachs Slides On Earnings MissJanuary 16, 2023 | finance.yahoo.comDow Jones Futures Fall With U.S. Markets Closed For MLK Holiday; Tesla's Big TransitionJanuary 13, 2023 | finance.yahoo.comInsulet (PODD) Stock Sinks As Market Gains: What You Should KnowJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 12, 2023 | finance.yahoo.comHow IBD Stock Of The Day Insulet Built A 'Moat' To Keep Out RivalsJanuary 12, 2023 | finance.yahoo.comInsulet to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023January 9, 2023 | finance.yahoo.comInsulet (PODD) Gains As Market Dips: What You Should KnowJanuary 2, 2023 | finance.yahoo.comInsulet Corporation (PODD) Stock Historical Prices & Data - Yahoo FinanceDecember 28, 2022 | finance.yahoo.comInsulet's (PODD) Omnipod Sales Aid, Costs Continue to RiseDecember 22, 2022 | finance.yahoo.comIs Insulet About to Continue Its Move Higher?December 8, 2022 | finance.yahoo.com2 Best Medical Device Stocks for 2023December 5, 2022 | finance.yahoo.comInsulet (NASDAQ:PODD) rallies 4.9% this week, taking five-year gains to 342%November 30, 2022 | finance.yahoo.comIBD Stock Of The Day: Why An Analyst Says The Rich Valuation For Insulet Is JustifiedNovember 18, 2022 | finance.yahoo.comFDA ranks Insulet's recall of insulin pump as among its 'most serious'November 17, 2022 | finance.yahoo.comInsulet recalls insulin pump remote; FDA ranks it as its 'most serious type'November 16, 2022 | finance.yahoo.comMedical Device Maker Insulet Is Poised for an Upside BreakoutNovember 15, 2022 | finance.yahoo.comInsulet Issues Medical Device Correction For Omnipod 5 Controller Due To Faulty ChargingNovember 14, 2022 | finance.yahoo.comInsulet Issues a Nationwide Voluntary Medical Device Correction for the Omnipod® 5 ControllerNovember 9, 2022 | finance.yahoo.comInsulet (PODD) Q3 Earnings Beat Estimates, '22 Sales View UpNovember 8, 2022 | finance.yahoo.comInsulet Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 4, 2022 | finance.yahoo.comInsulet Issued Voluntary Medical Device Correction for Omnipod DASH® Personal Diabetes Manager on October 17, 2022November 4, 2022 | finance.yahoo.comWhy Insulet Stock Is Skyrocketing TodaySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address PODD Company Calendar Last Earnings11/03/2022Today1/31/2023Next Earnings (Confirmed)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees2,300Year Founded2000Price Target and Rating Average Stock Price Forecast$312.08 High Stock Price Forecast$345.00 Low Stock Price Forecast$245.00 Forecasted Upside/Downside+8.0%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$0.24 Trailing P/E Ratio1,192.50 Forward P/E Ratio328.97 P/E GrowthN/ANet Income$16.80 million Net Margins1.35% Pretax Margin1.68% Return on Equity18.19% Return on Assets4.02% Debt Debt-to-Equity Ratio3.22 Current Ratio3.98 Quick Ratio3.00 Sales & Book Value Annual Sales$1.10 billion Price / Sales18.09 Cash Flow$1.08 per share Price / Cash Flow265.37 Book Value$8.07 per share Price / Book35.46Miscellaneous Outstanding Shares69,450,000Free Float68,824,000Market Cap$19.88 billion OptionableOptionable Beta0.79 Social Links Key ExecutivesJames R. HollingsheadPresident, Chief Executive Officer & DirectorPrem SinghSenior Vice President-Global OperationsWayde Dwight McMillanChief Financial Officer, Treasurer & Executive VPTrang LySenior Vice President & Medical DirectorMichael P. SpearsSenior VP-Quality, Regulatory Affairs & ComplianceKey CompetitorsAbiomedNASDAQ:ABMDBaxter InternationalNYSE:BAXTeleflexNYSE:TFXGlobus MedicalNYSE:GMEDResMedNYSE:RMDView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Sold 1,330 shares on 1/30/2023Ownership: 0.287%New York State Common Retirement FundBought 5,424 shares on 1/30/2023Ownership: 0.137%Natixis Advisors L.P.Bought 1,576 shares on 1/27/2023Ownership: 0.033%Joel Isaacson & Co. LLCBought 961 shares on 1/27/2023Ownership: 0.001%Inspire Investing LLCSold 96 shares on 1/26/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions PODD Stock - Frequently Asked Questions Should I buy or sell Insulet stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PODD shares. View PODD analyst ratings or view top-rated stocks. What is Insulet's stock price forecast for 2023? 13 brokerages have issued 1-year target prices for Insulet's shares. Their PODD share price forecasts range from $245.00 to $345.00. On average, they anticipate the company's stock price to reach $312.08 in the next year. This suggests a possible upside of 9.0% from the stock's current price. View analysts price targets for PODD or view top-rated stocks among Wall Street analysts. How have PODD shares performed in 2023? Insulet's stock was trading at $294.39 at the start of the year. Since then, PODD shares have decreased by 2.8% and is now trading at $286.20. View the best growth stocks for 2023 here. When is Insulet's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our PODD earnings forecast. How can I listen to Insulet's earnings call? Insulet will be holding an earnings conference call on Thursday, February 23rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) released its quarterly earnings data on Thursday, November, 3rd. The medical instruments supplier reported $0.45 EPS for the quarter, beating the consensus estimate of $0.17 by $0.28. The medical instruments supplier earned $340.80 million during the quarter, compared to analyst estimates of $311.84 million. Insulet had a net margin of 1.35% and a trailing twelve-month return on equity of 18.19%. What guidance has Insulet issued on next quarter's earnings? Insulet updated its fourth quarter 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $341.55 million-$350.78 million, compared to the consensus revenue estimate of $328.46 million. What is Shacey Petrovic's approval rating as Insulet's CEO? 61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD). What is Insulet's stock symbol? Insulet trades on the NASDAQ under the ticker symbol "PODD." Who are Insulet's major shareholders? Insulet's stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.65%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), AEGON ASSET MANAGEMENT UK Plc (0.27%), Beacon Investment Advisory Services Inc. (0.27%), Scout Investments Inc. (0.22%) and New York State Common Retirement Fund (0.14%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, Dan Manea, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Insulet's stock price today? One share of PODD stock can currently be purchased for approximately $286.20. How much money does Insulet make? Insulet (NASDAQ:PODD) has a market capitalization of $19.88 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.24 on an earnings per share basis. How many employees does Insulet have? The company employs 2,300 workers across the globe. How can I contact Insulet? Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120. This page (NASDAQ:PODD) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.